(firstQuint)Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK.

 The initial purpose of the study is to determine the largest amount of ensartinib that can be safely given to humans.

 An expansion phase will be conducted to assess the preliminary anti-tumor activity in ALK-positive non-small cell lung cancer once the recommended Phase 2 dose has been established.

.

 Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK@highlight

This study is aimed to determine the maximum tolerated dose of ensartinib, an oral ALK inhibitor in Chinese patients with ALK-positive non-small cell lung cancer